Mont-Saint-Guibert, Belgium – 15 December 2021 – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 10, 2021 indicating that CFIP CLYD LLC, an affiliate of Fortress Investment Group LLC, has crossed the statutory threshold of 25%, holding 6,500,000 shares i.e. 28.77% of Celyad Oncology’s shares and 26.04% voting rights as of 8 December 2021.
Content of the Notification:
- Reason of the Notification:
Upward crossing of the 25% threshold
Acquisition of voting securities or voting rights
- Notification by:
A parent undertaking or a controlling person
- Persons subject to the notification requirement:
Fortress Investment Group LLC. – 1345 Avenue of the Americas, 46th Floor, New York, NY 10105 USA
CFIP CLYD LLC – 1345 Avenue of the Americas, 46th Floor, New York, NY 10105 USA
- Transaction date
December 8, 2021
- Threshold that is crossed (in %)
- Notified details:
|A) Voting Rights||Previous notification||After the Transaction|
|#of voting rights||# of voting rights||% of voting rights|
|Holders of voting rights||Linked to the securities||Not linked to the securities||Linked to the securities||Not linked to the securities|
|Fortress Investment Group LLC||0||0.00%|
|CFIP CLYD LLC||6,500,000||26.04%|
Fortress Investment Group LLC indirectly controls 100% of the members of CFIP CLYD LLC, which are various Fortress Funds. Fortress Investment Group LLC has no controlling shareholder.
- The Press Release may be consulted on the website of Celyad Oncology via this link.
The notification can be consulted on the website if Celyad Oncology via this link.
- Contact person(s):
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): email@example.com.